| Name | Title | Contact Details |
|---|---|---|
Chris Hodes |
Regional Sales Director | Profile |
Steve O'Brien |
SVP, Talent Acquisition | Profile |
Hillary Bochniak |
Chief Human Resources Officer | Profile |
Robyn Aycock |
Regional Sales Director-Southeast | Profile |
Stanford Rudnick |
Interim Chief Financial Officer and Chief Strategy Officer | Profile |
SK Biopharmaceuticals is a Fairfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.
U.S. Urology Partners is a physician-led management services organization that provides business support services to our network of urology practices .
Noninvasive monitoring that enables less invasive care. My care setting is: MORE Noninvasive monitoring that enables less invasive care. My care setting is: MORE
OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure`s drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.